Skip to content
Disclosery

B Group, Inc.

Follow

13F filer, CIK 2043476, DALLAS, TX

B Group, Inc. reported $135,948,346 across 20 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14. Its ten largest share positions make up 90.85% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-25-003231

Period
2025-09-30
Reported value
$136M
Holdings
20
Top 10 weight
90.85%
New
5
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
NRXPWnew+3,000,000$4.46M
ADMAadded+95,000$1.39M
RAREadded+25,000$752K
SYREadded+20,000$335K
GAMEnew+250,000$170K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
INSMreduced-154,842-$22.3M
ASMBreduced-13,644-$349K
PRAXreduced-3,500-$186K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001420506-25-003231, largest first. % of portfolio is the value over $104,577,846, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ADMAADMA BIOLOGICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,287,542 shares; 2025Q1: 2,317,542 shares; 2025Q2: 2,317,542 shares; 2025Q3: 2,412,542 shares 2,412,542$35.4M33.82%+95,000Timeline
ZLABZAI LAB LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 400,000 shares; 2025Q1: 400,000 shares; 2025Q2: 400,000 shares; 2025Q3: 400,000 shares 400,000$13.6M12.96%0Timeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 260,000 shares; 2025Q1: 242,500 shares; 2025Q2: 232,446 shares; 2025Q3: 232,446 shares 232,446$11M10.55%0Timeline
CLLSCELLECTIS S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,081,501 shares; 2025Q1: 3,256,501 shares; 2025Q2: 3,256,501 shares; 2025Q3: 3,281,501 shares 3,281,501$9.35M8.94%+25,000Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 965,556 shares; 2025Q1: 1,255,556 shares; 2025Q2: 1,800,556 shares; 2025Q3: 1,800,556 shares 1,800,556$5.89M5.63%0Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 50,651 shares; 2025Q1: 200,000 shares; 2025Q2: 189,350 shares; 2025Q3: 175,706 shares 175,706$4.5M4.3%-13,644Timeline
NRXPWNRX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 3,000,000 shares 3,000,000$4.46M4.26%newTimeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 7,596 shares; 2025Q1: 47,500 shares; 2025Q2: 110,000 shares; 2025Q3: 135,000 shares 135,000$4.06M3.88%+25,000Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 472,576 shares; 2025Q1: 472,576 shares; 2025Q2: 572,576 shares; 2025Q3: 572,576 shares 572,576$3.54M3.38%0Timeline
IOVAIOVANCE BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 992,000 shares; 2025Q1: 1,500,000 shares; 2025Q2: 1,500,000 shares; 2025Q3: 1,500,000 shares 1,500,000$3.25M3.11%0Timeline
SGHTSIGHT SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 629,370 shares; 2025Q1: 833,600 shares; 2025Q2: 930,000 shares; 2025Q3: 930,000 shares 930,000$3.2M3.06%0Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 50,000 shares; 2025Q1: 70,000 shares; 2025Q2: 80,000 shares; 2025Q3: 100,000 shares 100,000$1.68M1.6%+20,000Timeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: 19,000 shares; 2025Q2: 35,000 shares; 2025Q3: 31,500 shares 31,500$1.67M1.6%-3,500Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 20,000 shares; 2025Q1: 58,215 shares; 2025Q2: 75,000 shares; 2025Q3: 75,000 shares 75,000$1.44M1.38%0Timeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 15,000 shares; 2025Q1: 30,000 shares; 2025Q2: 35,000 shares; 2025Q3: 35,000 shares 35,000$1.39M1.33%0Timeline
GAMEGAMESQUARE HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 250,000 shares 250,000$170K0.16%newTimeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 350,000 shares; 2025Q1: 262,500 shares; 2025Q2: 155,000 shares; 2025Q3: 158 shares 158$22.8K0.02%-154,842Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
LLYELI LILLY & CO COMput22,500$17.2Mnew
NVDANVIDIA CORPORATION COMput75,000$14Mnew
REPLREPLIMUNE GROUP INC COMMON STOCKcall50,000$210Knew

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ELI LILLY & COELI LILLY & CO15,000$11.7Mput
ULTRAGENYX PHARMACEUTICAL INULTRAGENYX PHARMACEUTICAL IN67,600$2.46Mcall

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-25-003231 base2025-11-14acceptance time not in the bulk data set